Key result
Combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists is advocated as a beneficial clinical strategy rather than choosing between the two classes.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Alice Cheng (2021) studied this question. Combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists is advocated as a beneficial clinical strategy rather than choosing between the two classes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: